Primary surgery for oropharyngeal cancer

被引:6
作者
Udoff, Ross A. [2 ]
Elam, Jackson C. [2 ]
Gourin, Christine G. [1 ]
机构
[1] Johns Hopkins Med Inst, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21287 USA
[2] Med Coll Georgia, Dept Otolaryngol Head & Neck Surg, Augusta, GA 30912 USA
关键词
SQUAMOUS-CELL CARCINOMA; TRANSORAL LATERAL OROPHARYNGECTOMY; HUMAN-PAPILLOMAVIRUS; SALVAGE SURGERY; TONSILLAR REGION; SURVIVAL; OUTCOMES; NECK; HEAD; CHEMORADIATION;
D O I
10.1016/j.otohns.2010.06.922
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
OBJECTIVE: The development of new techniques for transoral resection has led to a renewed interest in primary surgical treatment of oropharyngeal squamous cell cancer (SCCA) We reviewed our experience with primary surgery for oropharyngeal SCCA to identify factors associated with survival STUDY DESIGN: Case series with chart review SETTING: Tertiary medical center. SUBJECTS AND METHODS: Patients who underwent primary surgical treatment of oropharyngeal SCCA from 1985 to 2002 were analyzed. Patients who failed nonoperative treatment or had distant metastases at presentation were excluded RESULTS: A total of 105 patients met study criteria The majority of patients (91%) had advanced stage disease (III/IV) All patients received postoperative radiation, chemotherapy was used in eight patients. Five-year disease-free survival was 83 percent for stage I, 67 percent for stage II, 56 percent for stage III, and 43 percent for stage IV disease Crude local control rates were 94 percent for T1 disease, 90 percent for T2 disease, 81 percent for T3 disease, and 80 percent for T4 disease; crude regional control rates were 100 percent for NO disease, 90 percent for NI disease, 84 percent for N2 disease, and 82 percent for N3 disease Cox proportional hazards models revealed that nodal stage (hazard ratio [FIR] 2 3, P = 0 02) and black race (HR 2 6, P = 0.004) were the only significant predictors of disease-free survival CONCLUSION: Primary surgical treatment of oropharyngeal SCCA is effective in achieving excellent locoregional control and permits deintensification of adjuvant therapy, even in patients with advanced stage disease Nodal status and race are the primary determinants of disease-free survival. These data provide useful Information for counseling and treatment planning. (C) 2010 American Academy of Otolaryngology Head and Neck Surgery Foundation All rights reserved
引用
收藏
页码:644 / 649
页数:6
相关论文
共 50 条
  • [21] Prognostic value of pretherapy platelet elevation in oropharyngeal cancer patients treated with chemoradiation
    Shoultz-Henley, Sara
    Garden, Adam S.
    Mohamed, Abdallah S. R.
    Sheu, Tommy
    Kroll, Michael H.
    Rosenthal, David I.
    Gunn, G. Brandon
    Hayes, Amos J.
    French, Chloe
    Eichelberger, Hillary
    Kalpathy-Cramer, Jayashree
    Smith, Blaine D.
    Phan, Jack
    Ayoub, Zeina
    Lai, Stephen Y.
    Pham, Brian
    Kies, Merrill
    Gold, Kathryn A.
    Sturgis, Erich
    Fuller, Clifton D.
    INTERNATIONAL JOURNAL OF CANCER, 2016, 138 (05) : 1290 - 1297
  • [22] Transoral Robotic Surgery and Human Papillomavirus Infection: Impact on Oropharyngeal Cancer Prognosis
    Chen, Jingtao
    Zhang, Xing
    Yan, Shida
    Li, Xiyuan
    Li, Menghua
    Zhang, Ying
    Zhang, Shiting
    Li, Fengjiao
    Song, Ming
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (15)
  • [23] Human Papillomavirus: Changing Paradigms in Oropharyngeal Cancer
    Adelstein, David J.
    Rodriguez, Cristina P.
    CURRENT ONCOLOGY REPORTS, 2010, 12 (02) : 115 - 120
  • [24] Prognostic utility of basaloid differentiation in oropharyngeal cancer
    Cooper, Timothy
    Biron, Vincent
    Adam, Ben
    Klimowicz, Alexander C.
    Puttagunta, Lakshmi
    Seikaly, Hadi
    JOURNAL OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2013, 42
  • [25] Evidence-based management of oropharyngeal cancer
    Robson, A. K.
    Paleri, V
    CLINICAL OTOLARYNGOLOGY, 2010, 35 (04) : 273 - 276
  • [26] Comparative effectiveness trial of transoral head and neck surgery followed by adjuvant radio(chemo)therapy versus primary radiochemotherapy for oropharyngeal cancer (TopROC)
    Bussmann, Lara
    Laban, Simon
    Wittekindt, Claus
    Stromberger, Carmen
    Tribius, Silke
    Moeckelmann, Nikolaus
    Boettcher, Arne
    Betz, Christian Stephan
    Klussmann, Jens Peter
    Budach, Volker
    Muenscher, Adrian
    Busch, Chia-Jung
    BMC CANCER, 2020, 20 (01)
  • [27] Current Indications for Transoral Robotic Surgery in Oropharyngeal Cancer
    Parhar, Harman S.
    Yver, Christina M.
    Brody, Robert M.
    OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA, 2020, 53 (06) : 949 - +
  • [28] Primary surgery versus (chemo)radiotherapy in oropharyngeal cancer: the radiation oncologist's and medical oncologist's perspectives
    Huang, Shao Hui
    Hansen, Aaron
    Rathod, Shrinivas
    O'Sullivan, Brian
    CURRENT OPINION IN OTOLARYNGOLOGY & HEAD AND NECK SURGERY, 2015, 23 (02) : 139 - 147
  • [29] Predictors of survival in patients undergoing oropharyngeal surgery for cancer recurrence after radiation therapy
    Neal, Molly E. Heft
    Brennan, Julia
    Haring, Catherine T.
    Brenner, J. Chad
    Worden, Francis
    Swiecicki, Paul
    Mierzwa, Michelle
    Casper, Keith A.
    Malloy, Kelly M.
    Stucken, Chaz L.
    McLean, Scott A.
    Prince, Mark E.
    Bradford, Carol R.
    Wolf, Gregory T.
    Shuman, Andrew G.
    Chinn, Steven B.
    Chepeha, Douglas B.
    Rosko, Andrew J.
    Spector, Matthew E.
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2020, 277 (07) : 2085 - 2093
  • [30] Management of Recurrent and Metastatic HPV-Positive Oropharyngeal Squamous Cell Carcinoma after Transoral Robotic Surgery
    Sims, John R.
    Van Abel, Kathryn
    Martin, Eliot J.
    Lohse, Christine M.
    Price, Daniel L.
    Olsen, Kerry D.
    Moore, Eric J.
    OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2017, 157 (01) : 69 - 76